Tomoya Kawaguchi

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Dynamic stability of active sites in hydr(oxy)oxides for the oxygen evolution reaction

Dong Young Chung, Pietro Papa Lopes, Pedro Farinazzo Bergamo Dias Martins et al. · Nature Energy · 2020 · 942 citations · Full text

Oxygen Reduction Reaction, Chemical Engineering, Engineering +10

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLC

Tomoya Kawaguchi, Minoru Takada, Akihito Kubo et al. · Journal of Thoracic Oncology · 2010 · 351 citations

Tobacco Control, Advanced Lung Disease, Medicine +9

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2014 · 261 citations · Full text

Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR

Masaru Watanabe, Tomoya Kawaguchi, Shun‐ichi Isa et al. · Clinical Cancer Research · 2015 · 222 citations